SV1999000061A - Agonistas y antagonistas il-2 selectivos ref. 5038p1-sv - Google Patents
Agonistas y antagonistas il-2 selectivos ref. 5038p1-svInfo
- Publication number
- SV1999000061A SV1999000061A SV1999000061A SV1999000061A SV1999000061A SV 1999000061 A SV1999000061 A SV 1999000061A SV 1999000061 A SV1999000061 A SV 1999000061A SV 1999000061 A SV1999000061 A SV 1999000061A SV 1999000061 A SV1999000061 A SV 1999000061A
- Authority
- SV
- El Salvador
- Prior art keywords
- cells
- agonists
- ref
- antagonists
- selective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
LA PRESENTE INVENCIÓN ESTA ORIENTADA A UN POLIPÉPTIDO QUE COMPRENDE UNA MUTEÍNA DE IL-2 HUMANA NUMERADA DE ACUERDO CON LA IL-2 DE TIPO SALVAJE EN LA CUAL DICHA IL-2 HUMANA ESTA SUSTITUIDA EN POR LO MENOS UNA DE LAS POSICIONES 20, 88 Ó 126, CON LO CUAL DICHA MUTEÍNA ACTIVA CÉLULAS T CON MAYOR PREFERENCIA CON RESPECTO A LAS CÉLULAS NK. EL D2OH E I, N88G, I, Y R, EN PARTICULAR, TIENEN UNA ACTIVIDAD DIFERENCIAL PARA LAS CÉLULAS T, MUCHO MAYOR QUE LA IL-2 NATIVA, CON UNA TOXICIDAD IN VIVO ASOCIADA PREDICHA, REDUCIDA. LA INVENCIÓN TAMBIÉN PROVEE POLINUCLEÓTIDOS QUE CODIFICAN LAS MUTEÍNAS DE LA INVENCIÓN, VECTORES QUE CONTIENEN LOS POLINUCLEÓTIDOS, CÉLULAS HOSPEDANTES TRANSFORMADAS, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LAS MUTEÍNAS, Y MÉTODOS TERAPÉUTICOS DE TRATAMIENTO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8008098A | 1998-05-15 | 1998-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV1999000061A true SV1999000061A (es) | 2000-03-14 |
Family
ID=22155135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV1999000061A SV1999000061A (es) | 1998-05-15 | 1999-05-14 | Agonistas y antagonistas il-2 selectivos ref. 5038p1-sv |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1076704B1 (es) |
JP (1) | JP4276783B2 (es) |
KR (1) | KR100607609B1 (es) |
CN (2) | CN101319247B (es) |
AR (1) | AR020322A1 (es) |
AT (1) | ATE351907T1 (es) |
AU (1) | AU759697B2 (es) |
BG (1) | BG65139B1 (es) |
BR (1) | BRPI9910504B1 (es) |
CA (1) | CA2327349C (es) |
CO (1) | CO5070701A1 (es) |
CU (2) | CU23273B7 (es) |
CY (1) | CY1107533T1 (es) |
CZ (1) | CZ302071B6 (es) |
DE (1) | DE69934881T2 (es) |
DK (1) | DK1076704T3 (es) |
DZ (1) | DZ2788A1 (es) |
ES (1) | ES2281175T3 (es) |
HK (1) | HK1039963B (es) |
HN (1) | HN1999000075A (es) |
HU (1) | HU226142B1 (es) |
IL (2) | IL139136A0 (es) |
MY (1) | MY130274A (es) |
NO (1) | NO329235B1 (es) |
NZ (1) | NZ508098A (es) |
PA (1) | PA8472601A1 (es) |
PE (1) | PE20000475A1 (es) |
PL (1) | PL201675B1 (es) |
PT (1) | PT1076704E (es) |
RO (1) | RO122150B1 (es) |
RU (1) | RU2235729C2 (es) |
SI (1) | SI20643B (es) |
SK (1) | SK288100B6 (es) |
SV (1) | SV1999000061A (es) |
TN (1) | TNSN99090A1 (es) |
TR (1) | TR200003354T2 (es) |
TW (1) | TWI223663B (es) |
UA (1) | UA73719C2 (es) |
WO (1) | WO1999060128A1 (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566500B1 (en) | 1999-03-30 | 2003-05-20 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
ES2359473T3 (es) * | 2003-07-21 | 2011-05-23 | Transgene S.A. | Citoquinas multifuncionales. |
EP1694360B1 (en) | 2003-11-04 | 2010-08-04 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
JP5744369B2 (ja) * | 2004-02-27 | 2015-07-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | IL15−Rα用IL−15結合部位およびアゴニスト/アンタゴニスト活性を有する特異的IL−15突然変異体 |
RU2006135112A (ru) * | 2004-03-05 | 2008-04-10 | Чирон Корпорейшн (Us) | Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам |
WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
CN101244261B (zh) * | 2008-03-10 | 2010-09-15 | 山东大学 | 一种含未复性重组蛋白的生物制剂及其制备方法与应用 |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
CA2749539C (en) | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
PT2637694T (pt) | 2010-11-12 | 2021-05-05 | Nektar Therapeutics | Conjugados de uma fração de il-2 e um polímero |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
DK3489255T3 (da) | 2011-02-10 | 2021-08-23 | Roche Glycart Ag | Muterede interleukin-2-polypeptider |
WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
MA39250B1 (fr) | 2014-02-06 | 2018-09-28 | Hoffmann La Roche | Protéines hybrides de l'interleukine-2 et leurs utilisations |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA2946398A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
SG11201700629TA (en) * | 2014-08-11 | 2017-02-27 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
WO2017201432A2 (en) * | 2016-05-19 | 2017-11-23 | Jounaidi Youssef | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
EP3475413B1 (en) | 2016-06-22 | 2024-02-14 | David Klatzmann | Genetically modified t lymphocytes |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
BR112019011799B1 (pt) * | 2016-12-13 | 2021-12-21 | Delinia, Inc | Proteína de fusão, proteína dimérica e composição farmacêutica |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
EP3630162A1 (en) * | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
JOP20190271A1 (ar) * | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
US11542312B2 (en) | 2017-06-19 | 2023-01-03 | Medicenna Therapeutics, Inc. | IL-2 superagonists in combination with anti-PD-1 antibodies |
US20200181220A1 (en) * | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
US20200299349A1 (en) * | 2017-11-21 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたil−2 fc融合タンパク質 |
EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
MX2020009975A (es) | 2018-03-28 | 2020-10-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso. |
AU2019246389A1 (en) | 2018-03-28 | 2020-08-27 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
CA3106858A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Il2 agonists |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
MX2020007072A (es) * | 2018-09-17 | 2020-11-11 | Gi Innovation Inc | Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma. |
TW202034945A (zh) | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素2變體或其衍生物 |
BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
MX2022001866A (es) * | 2019-08-13 | 2022-03-11 | Amgen Inc | Muteinas de interleucina-2 para la expansion de celulas t reguladoras. |
JP2023505590A (ja) | 2019-12-12 | 2023-02-09 | イルトゥー・ファルマ | インターロイキン2キメラ構築物 |
CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
KR102653906B1 (ko) | 2020-01-14 | 2024-04-03 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
KR20220155316A (ko) | 2020-03-19 | 2022-11-22 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 인터루킨-2 돌연변이 및 이의 용도 |
AR121713A1 (es) | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
EP4161956A1 (en) | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
KR20230097094A (ko) | 2020-10-29 | 2023-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | 질환의 치료를 위한 융합 단백질 |
CN113308477A (zh) * | 2021-04-08 | 2021-08-27 | 华南农业大学 | 一种鸭il-2基因真核表达重组质粒及其制备方法 |
TW202320862A (zh) | 2021-09-22 | 2023-06-01 | 大陸商信達生物製藥(蘇州)有限公司 | 介白素2突變體以及其融合蛋白 |
WO2023057588A1 (en) | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
WO2023245097A2 (en) * | 2022-06-16 | 2023-12-21 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
FR3140287A1 (fr) | 2022-10-03 | 2024-04-05 | Arkema France | Procede de granulation de composes azoiques et granules obtenus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
-
1999
- 1999-05-12 DZ DZ990088A patent/DZ2788A1/xx active
- 1999-05-13 RO ROA200001123A patent/RO122150B1/ro unknown
- 1999-05-13 PT PT99924232T patent/PT1076704E/pt unknown
- 1999-05-13 IL IL13913699A patent/IL139136A0/xx unknown
- 1999-05-13 NZ NZ508098A patent/NZ508098A/en not_active IP Right Cessation
- 1999-05-13 UA UA2000127206A patent/UA73719C2/uk unknown
- 1999-05-13 PA PA19998472601A patent/PA8472601A1/es unknown
- 1999-05-13 BR BRPI9910504A patent/BRPI9910504B1/pt not_active IP Right Cessation
- 1999-05-13 AT AT99924232T patent/ATE351907T1/de active
- 1999-05-13 DK DK99924232T patent/DK1076704T3/da active
- 1999-05-13 SK SK1724-2000A patent/SK288100B6/sk not_active IP Right Cessation
- 1999-05-13 CN CN2007101609093A patent/CN101319247B/zh not_active Expired - Lifetime
- 1999-05-13 WO PCT/US1999/010643 patent/WO1999060128A1/en active IP Right Grant
- 1999-05-13 RU RU2000131593/04A patent/RU2235729C2/ru active
- 1999-05-13 AR ARP990102269A patent/AR020322A1/es active IP Right Grant
- 1999-05-13 PL PL344407A patent/PL201675B1/pl unknown
- 1999-05-13 EP EP99924232A patent/EP1076704B1/en not_active Expired - Lifetime
- 1999-05-13 PE PE1999000399A patent/PE20000475A1/es not_active Application Discontinuation
- 1999-05-13 TN TNTNSN99090A patent/TNSN99090A1/fr unknown
- 1999-05-13 CA CA2327349A patent/CA2327349C/en not_active Expired - Lifetime
- 1999-05-13 HU HU0101948A patent/HU226142B1/hu unknown
- 1999-05-13 AU AU40784/99A patent/AU759697B2/en not_active Expired
- 1999-05-13 TR TR2000/03354T patent/TR200003354T2/xx unknown
- 1999-05-13 JP JP2000549735A patent/JP4276783B2/ja not_active Expired - Lifetime
- 1999-05-13 DE DE69934881T patent/DE69934881T2/de not_active Expired - Lifetime
- 1999-05-13 CN CNB998086509A patent/CN100366742C/zh not_active Expired - Lifetime
- 1999-05-13 SI SI9920034A patent/SI20643B/sl active Search and Examination
- 1999-05-13 ES ES99924232T patent/ES2281175T3/es not_active Expired - Lifetime
- 1999-05-13 KR KR1020007012747A patent/KR100607609B1/ko not_active IP Right Cessation
- 1999-05-13 CZ CZ20004213A patent/CZ302071B6/cs not_active IP Right Cessation
- 1999-05-14 CO CO99030158A patent/CO5070701A1/es unknown
- 1999-05-14 HN HN1999000075A patent/HN1999000075A/es unknown
- 1999-05-14 TW TW088107812A patent/TWI223663B/zh not_active IP Right Cessation
- 1999-05-14 SV SV1999000061A patent/SV1999000061A/es active IP Right Grant
- 1999-05-14 MY MYPI99001912A patent/MY130274A/en unknown
-
2000
- 2000-10-18 IL IL139136A patent/IL139136A/en not_active IP Right Cessation
- 2000-11-08 BG BG104929A patent/BG65139B1/bg unknown
- 2000-11-14 NO NO20005762A patent/NO329235B1/no not_active IP Right Cessation
- 2000-11-15 CU CU20000257A patent/CU23273B7/es not_active IP Right Cessation
-
2002
- 2002-02-21 HK HK02101283.2A patent/HK1039963B/zh not_active IP Right Cessation
- 2002-06-19 CU CU20020125A patent/CU23272A1/es not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100330T patent/CY1107533T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV1999000061A (es) | Agonistas y antagonistas il-2 selectivos ref. 5038p1-sv | |
ES2171768T3 (es) | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. | |
AR036711A1 (es) | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico | |
PT1161548E (pt) | Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus | |
GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
UY25794A1 (es) | Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a | |
BR9907189A (pt) | Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso | |
AR003641A1 (es) | Composiciones y metodos para controlar los hongos perjudiciales. | |
GT200000014A (es) | Derivados de quinolin - 2 - ona sustituidos con heteroarilo utiles como agentes anticancerigenos. | |
DE3687763D1 (de) | Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen. | |
EA200000379A1 (ru) | Усеченные по амино-концу rantes как антагонисты хемокинов | |
AR041061A1 (es) | Uso de la eritropoyetina en pacientes con diabetes | |
AR021695A1 (es) | 4,5-pirazinoxindoles, composicion farmaceutica y uso | |
ES2055415T3 (es) | S-adenosil-metionina para el tratamiento de pancreatitis y del inmunorechazo del trasplante de pancreas. | |
ES2172703T3 (es) | Composiciones de fluoruro de perfluoro(alcoxiciclo alcano)carbonilo, y su uso. | |
ES2154002T3 (es) | 2-naftoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene. | |
PA8461401A1 (es) | Derivados de eritromicina triciclicos | |
Groves | Only the paranoid survive | |
MX9203175A (es) | Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion. | |
ES2129893T3 (es) | Dinucleosido-5',5'-pirofosfatos. | |
ECSP992953A (es) | Agonistas y antagonistas il-2 selectivos (caso 5038p1-ec) | |
GT199500039A (es) | Compuestos ariltios | |
SV2002000418A (es) | Inhibidor del intercambiador de socio-hidrogeno de tipo 1 ref. pc1086aado/bb | |
ES2132283T3 (es) | Derivados n-heteroaril sustituidos de propanamida utiles en el tratamiento de enfermedades cardiovasculares. | |
ES2100055T3 (es) | Agentes de recubrimiento estañables para alambre asi como procedimientos para el recubrimiento continuo de alambres. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment | ||
FG | Grant |